Can a new antibody boost chemotherapy against advanced colorectal cancer?

NCT ID NCT07775287

Not yet recruiting Disease control Sponsor: Genmab Source: ClinicalTrials.gov ↗

First seen Aug 20, 2026 · Last updated Aug 21, 2026 · Updated 1 time

Summary

This trial is testing whether adding an experimental antibody called petosemtamab to standard chemotherapy can help people with a certain type of advanced colorectal cancer that has returned or spread. Participants will receive either petosemtamab plus chemotherapy or a standard treatment (cetuximab or bevacizumab) plus chemotherapy. The study aims to see if the new combination improves how long the cancer stays under control and how well tumors shrink, compared to current options.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
Petosemtamab, an experimental antibody, combined with chemotherapy (FOLFIRI or mFOLFOX6), compared to standard treatments (cetuximab or bevacizumab) plus chemotherapy.
What this could lead to
If successful, this could offer a new second-line treatment option for people with a specific type of advanced colorectal cancer, potentially slowing tumor growth and improving response rates.
What could go wrong
This is a phase 3 trial, but results are not guaranteed. The experimental combination may not be more effective than current standards and could cause additional side effects. Long-term benefits are still unknown.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for COLORECTAL CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

More trials for these conditions

Other studies related to the condition(s) this trial covers.